Galapagos NV (GLPGF)
USD 22.39
(0.0%)
USD 22.39
(0.0%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 4.35 Billion EUR | -7.96% |
| 2022 | 4.73 Billion EUR | -8.83% |
| 2021 | 5.19 Billion EUR | -9.17% |
| 2020 | 5.71 Billion EUR | -5.78% |
| 2019 | 6.06 Billion EUR | 321.58% |
| 2018 | 1.43 Billion EUR | 11.91% |
| 2017 | 1.28 Billion EUR | 18.73% |
| 2016 | 1.08 Billion EUR | 144.81% |
| 2015 | 442.51 Million EUR | 63.61% |
| 2014 | 270.46 Million EUR | -5.88% |
| 2013 | 287.37 Million EUR | 22.12% |
| 2012 | 235.32 Million EUR | 46.12% |
| 2011 | 161.05 Million EUR | -16.97% |
| 2010 | 193.96 Million EUR | 34.97% |
| 2009 | 143.7 Million EUR | 20.94% |
| 2008 | 118.82 Million EUR | -20.1% |
| 2007 | 148.72 Million EUR | -11.29% |
| 2006 | 167.64 Million EUR | 105.54% |
| 2005 | 81.56 Million EUR | 422.4% |
| 2004 | 15.61 Million EUR | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q1 | 4.36 Billion EUR | 0.09% |
| 2024 Q2 | 4.29 Billion EUR | -1.63% |
| 2023 Q2 | 4.52 Billion EUR | -2.37% |
| 2023 Q4 | 4.35 Billion EUR | -2.11% |
| 2023 Q1 | 4.63 Billion EUR | -2.16% |
| 2023 Q3 | 4.45 Billion EUR | -1.57% |
| 2023 FY | 4.35 Billion EUR | -7.96% |
| 2022 Q4 | 4.73 Billion EUR | -4.78% |
| 2022 FY | 4.73 Billion EUR | -8.83% |
| 2022 Q1 | 5.1 Billion EUR | -1.79% |
| 2022 Q2 | 5.04 Billion EUR | -1.18% |
| 2022 Q3 | 4.97 Billion EUR | -1.35% |
| 2021 Q3 | 5.33 Billion EUR | -1.82% |
| 2021 FY | 5.19 Billion EUR | -9.17% |
| 2021 Q4 | 5.19 Billion EUR | -2.6% |
| 2021 Q2 | 5.43 Billion EUR | -3.28% |
| 2021 Q1 | 5.61 Billion EUR | -1.8% |
| 2020 FY | 5.71 Billion EUR | -5.78% |
| 2020 Q1 | 5.99 Billion EUR | -1.26% |
| 2020 Q2 | 5.85 Billion EUR | -2.35% |
| 2020 Q3 | 5.72 Billion EUR | -2.23% |
| 2020 Q4 | 5.71 Billion EUR | -0.06% |
| 2019 Q2 | 1.35 Billion EUR | -3.02% |
| 2019 Q3 | 5.85 Billion EUR | 330.96% |
| 2019 Q4 | 6.06 Billion EUR | 3.71% |
| 2019 FY | 6.06 Billion EUR | 321.58% |
| 2019 Q1 | 1.4 Billion EUR | -2.73% |
| 2018 Q2 | 1.2 Billion EUR | -2.07% |
| 2018 Q3 | 1.48 Billion EUR | 23.35% |
| 2018 Q1 | 1.22 Billion EUR | -4.39% |
| 2018 FY | 1.43 Billion EUR | 11.91% |
| 2018 Q4 | 1.43 Billion EUR | -3.1% |
| 2017 Q3 | 1.33 Billion EUR | -2.7% |
| 2017 Q4 | 1.28 Billion EUR | -3.39% |
| 2017 FY | 1.28 Billion EUR | 18.73% |
| 2017 Q1 | 1.07 Billion EUR | -0.97% |
| 2017 Q2 | 1.36 Billion EUR | 27.55% |
| 2016 Q3 | 1.04 Billion EUR | -2.2% |
| 2016 FY | 1.08 Billion EUR | 144.81% |
| 2016 Q4 | 1.08 Billion EUR | 3.86% |
| 2016 Q2 | 1.06 Billion EUR | -1.18% |
| 2016 Q1 | 1.07 Billion EUR | 143.9% |
| 2015 Q4 | 442.51 Million EUR | -4.02% |
| 2015 Q1 | - EUR | -100.0% |
| 2015 FY | 442.51 Million EUR | 63.61% |
| 2015 Q2 | 488.26 Million EUR | 0.0% |
| 2015 Q3 | 461.04 Million EUR | -5.57% |
| 2014 Q4 | 270.46 Million EUR | 0.0% |
| 2014 FY | 270.46 Million EUR | -5.88% |
| 2014 Q1 | 304.98 Million EUR | 6.13% |
| 2014 Q2 | 304.98 Million EUR | 0.0% |
| 2013 Q3 | 287.37 Million EUR | 4.04% |
| 2013 FY | 287.37 Million EUR | 22.12% |
| 2013 Q2 | 276.22 Million EUR | 0.0% |
| 2013 Q1 | 276.22 Million EUR | 17.38% |
| 2013 Q4 | 287.37 Million EUR | 0.0% |
| 2012 Q4 | 235.32 Million EUR | 0.0% |
| 2012 FY | 235.32 Million EUR | 46.12% |
| 2012 Q2 | 243.33 Million EUR | 0.0% |
| 2011 Q4 | 161.05 Million EUR | 0.0% |
| 2011 Q2 | 152.98 Million EUR | 0.0% |
| 2011 FY | 161.05 Million EUR | -16.97% |
| 2010 Q4 | 193.96 Million EUR | 0.0% |
| 2010 Q2 | 139.73 Million EUR | 0.0% |
| 2010 FY | 193.96 Million EUR | 34.97% |
| 2009 Q2 | 106.21 Million EUR | 0.0% |
| 2009 FY | 143.7 Million EUR | 20.94% |
| 2009 Q4 | 143.7 Million EUR | 0.0% |
| 2008 Q4 | 118.82 Million EUR | 0.0% |
| 2008 FY | 118.82 Million EUR | -20.1% |
| 2007 FY | 148.72 Million EUR | -11.29% |
| 2006 FY | 167.64 Million EUR | 105.54% |
| 2005 FY | 81.56 Million EUR | 422.4% |
| 2004 FY | 15.61 Million EUR | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| ContraFect Corporation | 20.67 Million USD | -20971.599% |
| Eiger BioPharmaceuticals, Inc. | 38.84 Million USD | -11116.815% |
| Nanobac Pharmaceuticals, Incorporated | 7.21 Million USD | -60253.735% |
| Institute of Biomedical Research Corp. | 76.35 Thousand USD | -5706733.958% |
| SQZ Biotechnologies Company | 107.18 Million USD | -3965.228% |
| Intellipharmaceutics International Inc. | 1.43 Million USD | -304180.631% |
| Evofem Biosciences, Inc. | 10.55 Million USD | -41186.678% |
| Santhera Pharmaceuticals Holding AG | 130.21 Million USD | -3246.418% |
| Propanc Biopharma, Inc. | 72.36 Thousand USD | -6021313.667% |
| Marizyme, Inc. | 22.01 Million USD | -19692.783% |
| Genus plc | 1.02 Billion USD | -323.5% |
| Pharming Group N.V. | 462.85 Million USD | -841.419% |
| Therapeutic Solutions International, Inc. | 3.31 Million USD | -131423.701% |
| CNBX Pharmaceuticals Inc. | 499.03 Thousand USD | -873057.409% |
| Nymox Pharmaceutical Corporation | 627 Thousand USD | -694859.49% |
| RegeneRx Biopharmaceuticals, Inc. | 382.17 Thousand USD | -1140051.291% |
| IMV Inc. | 31.33 Million USD | -13806.382% |
| AXIM Biotechnologies, Inc. | 4.14 Million USD | -104998.236% |
| ONE Bio Corp. | 70.08 Million USD | -6117.257% |
| RVL Pharmaceuticals plc | 128.51 Million USD | -3290.706% |
| Neon Bloom, Inc. | 770.64 Thousand USD | -565322.685% |
| Mosaic ImmunoEngineering Inc. | 261.27 Thousand USD | -1667630.416% |
| Biomind Labs Inc. | 73.81 Thousand USD | -5902710.929% |
| American Oriental Bioengineering, Inc. | 446.3 Million USD | -876.318% |
| Oncotelic Therapeutics, Inc. | 30.01 Million USD | -14417.418% |
| Skye Bioscience, Inc. | 11.94 Million USD | -36392.848% |
| GlobeStar Therapeutics Corporation | - USD | -Infinity% |
| Mesoblast Limited | 667.9 Million USD | -552.402% |
| THC Farmaceuticals, Inc. | 2.74 Million USD | -158562.217% |
| Arch Therapeutics, Inc. | 1.95 Million USD | -222421.728% |
| Acro Biomedical Co., Ltd. | 687.48 Thousand USD | -633715.961% |
| Curative Biotechnology, Inc. | 2.6 Million USD | -167286.397% |
| GB Sciences, Inc. | 103.44 Thousand USD | -4212305.019% |
| MultiCell Technologies, Inc. | 126.22 USD | -3452223002.519% |
| Alpha Cognition Inc. | 2.45 Million USD | -177595.511% |
| HST Global, Inc. | 1526.00 USD | -285543543.512% |
| CSL Limited | 38.02 Billion USD | 88.54% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| Agentix Corp. | 261.39 Thousand USD | -1666896.695% |
| Halberd Corporation | 10.13 Thousand USD | -43010422.16% |
| Enzolytics Inc. | 361.7 Million USD | -1104.677% |
| Resverlogix Corp. | 8.11 Million USD | -53595.576% |
| Nuo Therapeutics, Inc. | 1.87 Million USD | -231938.043% |
| argenx SE | 4.54 Billion USD | 4.074% |
| Enzon Pharmaceuticals, Inc. | 47.7 Million USD | -9034.619% |
| Emmaus Life Sciences, Inc. | 35.17 Million USD | -12286.355% |
| Inhibitor Therapeutics, Inc. | 8.94 Million USD | -48590.586% |
| Bioxytran, Inc. | 137.63 Thousand USD | -3165737.923% |
| Zenith Capital Corp. | 7410.00 USD | -58804164.507% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 321.8 Thousand USD | -1353944.362% |
| WPD Pharmaceuticals Inc. | 261.36 Thousand USD | -1667075.28% |
| Cotinga Pharmaceuticals Inc. | 927.96 Thousand USD | -469466.717% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Adynxx, Inc. | - USD | -Infinity% |
| Genscript Biotech Corporation | 3.38 Billion USD | -28.674% |
| Kadimastem Ltd | 2.3 Million USD | -189016.524% |
| Helix BioMedix, Inc. | 3.02 Million USD | -143942.054% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Provectus Biopharmaceuticals, Inc. | 1.44 Million USD | -300650.047% |
| Capstone Therapeutics Corp. | 52.7 Million USD | -8168.147% |
| VioQuest Pharmaceuticals, Inc. | 1.35 Million USD | -320685.245% |
| PsyBio Therapeutics Corp. | 390.36 Thousand USD | -1116133.483% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Accustem Sciences Inc. | 939.68 Thousand USD | -463606.184% |
| EV Biologics, Inc. | 431.71 Thousand USD | -1009224.692% |
| Reve Technologies, Inc. | 57.09 Thousand USD | -7631868.333% |
| Q BioMed Inc. | 3.51 Million USD | -123847.516% |
| LadRx Corporation | 2.3 Million USD | -188704.974% |
| Cell Source, Inc. | 195.17 Thousand USD | -2232504.229% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| ProtoKinetix, Incorporated | 480.55 Thousand USD | -906638.639% |
| Regen BioPharma, Inc. | 353.61 Thousand USD | -1232136.007% |
| MetaStat, Inc. | - USD | -Infinity% |
| Northwest Biotherapeutics, Inc. | 27.94 Million USD | -15493.315% |
| Itoco Inc. | 1.4 Million USD | -311126.565% |
| Rasna Therapeutics, Inc. | 95.65 Thousand USD | -4555129.623% |
| Wesana Health Holdings Inc. | 987.96 Thousand USD | -440946.715% |
| Endonovo Therapeutics, Inc. | 639.65 Thousand USD | -681109.275% |
| Pathfinder Cell Therapy, Inc. | 106 Thousand USD | -4110650.943% |
| RespireRx Pharmaceuticals Inc. | 22.78 Thousand USD | -19127225.403% |
| GeneThera, Inc. | - USD | -Infinity% |
| AVAX Technologies, Inc. | 7.37 Million USD | -58966.06% |
| Ember Therapeutics, Inc. | 184.00 USD | -2368149900.0% |
| NovAccess Global Inc. | 62.24 Thousand USD | -6999957.833% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | 142.97 Thousand USD | -3047626.828% |
| BioStem Technologies, Inc. | 14.56 Million USD | -29826.572% |
| NanoSphere Health Sciences Inc. | 17.88 Thousand USD | -24370123.714% |
| Burzynski Research Institute, Inc. | 2310.00 USD | -188631761.472% |
| Qrons Inc. | 420.00 USD | -1037475138.095% |
| Alseres Pharmaceuticals, Inc. | 385.47 Thousand USD | -1130308.254% |
| SYBLEU INC | 330.46 Thousand USD | -1318453.082% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| Nascent Biotech, Inc. | 552.12 Thousand USD | -789111.766% |
| Rebus Holdings, Inc. | 5000.00 USD | -87147820.0% |
| Regen BioPharma, Inc. | 353.61 Thousand USD | -1232136.007% |
| ImmunoCellular Therapeutics, Ltd. | 409.42 Thousand USD | -1064179.887% |
| Affymax, Inc. | 7.44 Million USD | -58443.544% |
| Mobile Lads Corp. | 52.00 USD | -8379607592.308% |
| International Stem Cell Corporation | 5.39 Million USD | -80742.226% |
| CytoDyn Inc. | 11.13 Million USD | -39028.915% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 15 Million USD | -28945.763% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | - USD | -Infinity% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 16.57 Million USD | -26182.623% |
| Adhera Therapeutics, Inc. | 79 Thousand USD | -5515591.139% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 864.67 Thousand USD | -503833.376% |
| Innovation Pharmaceuticals Inc. | 7.51 Million USD | -57867.221% |
| Neutra Corp. | 2851.00 USD | -152837360.54% |
| Windtree Therapeutics, Inc. | 32.4 Million USD | -13346.263% |
| PureTech Health plc | 693.97 Million USD | -527.891% |
| Coeptis Therapeutics, Inc. | 8.07 Million USD | -53887.708% |
| IXICO plc | 15.84 Million USD | -27402.037% |
| IntelGenx Technologies Corp. | 8.28 Million USD | -52512.847% |
| Gelesis Holdings, Inc. | 103.32 Million USD | -4117.216% |
| CSL Limited | 38.02 Billion USD | 88.54% |
| Cellectis S.A. | 333.99 Million USD | -1204.631% |